Company Profiles

driven by the PitchBook Platform

Aranda Pharma

Aranda Pharma
2015 FOUNDED
PRIVATE STATUS
Seed LATEST DEAL TYPE
2 INVESTORS
Description

Developer of drugs intended to combat prostate cancer and neurodegenerative diseases. The company's drugs are made of small molecules and androgen receptor antagonist that are non-toxic, enabling patients to avail treatment at lower cost.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
Kuopio Science Park, Technopolis Business Center, Microkatu 1
Post Office Box 1199
70211 Kuopio
Finland

+358 (0)44 032 3361
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aranda Pharma’s full profile, request a free trial.

Aranda Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 04-Nov-2015 Completed Startup
1. Angel (individual) Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Aranda Pharma Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Finnvera Venture Capital Minority 000 0000 000000 0
Tarrex Biopharma Corporation Minority 000 0000 000000 0

You’re viewing 2 of 2 investors.

Aranda Pharma Executive Team (5)

Name Title Board
Seat
Contact
Info
Anu Muona Ph.D Chief Executive Officer & Co-Founder
Milla Koistinaho Ph.D Co-Founder & Board Member
Gundars Goldsteins Co-Founder & Scientific Collaborator
Heikki Eronen Manager, Company Administration and Finance
Jari Koistinaho Ph.D Co-Founder & Scientific Collaborator

You’re viewing 5 of 5 executives.

Aranda Pharma Board Members (4)

Name Representing Role Since Contact
Info
Aki Prihti Self Board Member 000 0000
Jussi Holopainen Self Chairman 000 0000
Kanyin Zhang Ph.D Tarrex Biopharma Board Member 000 0000
Milla Koistinaho Ph.D Aranda Pharma Co-Founder & Board Member 000 0000

You’re viewing 4 of 4 board members.